Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

cently filed Quarterly Report on Form 10-Q. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

Condensed Statements of Operations

(Unaudited)

(in thousands)

Three Months Nine Months

Ended Ended

September 30, September 30,

2008 2007 2008 2007

Operating expenses

Research and development $ 1,639 $ 1,094 $ 3,621 $ 3,075

General and administrative 1,024 609 2,243 2,709

------------------- -------------------

Total operating expenses 2,663 1,703 5,864 5,784

------------------- -------------------

Other income (expense) 297 (27) 88 44

------------------- -------------------

Loss for the period before taxes (2,366) (1,730) (5,776) (5,740)

Income tax expense (recovery) (2,515) 200 (2,100) 573

------------------- -------------------

Operating income (loss) before

extraordinary gain 149 (1,930) (3,676) (6,313)

Extraordinary gain 4,428 - 4,428 -

-------------------
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 According ... “Global Orthobiologics Market” the global orthobiologics market was valued at ... a market worth USD 5,519.9million in 2019at a CAGR of ... population aged 50 years and above is afflicted by bone ... double by the year 2020. This has and will continue ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Biotech Products, L.P. today announced that data related to ... Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, ... The studies were sponsored by Centocor Ortho Biotech Products, ... and Development, a unit of Johnson & Johnson Pharmaceutical ...
... 28 Plexus Corp. (Nasdaq: PLXS ) announced ... generation automated screening system for the pre-processing of human papillomavirus ... solution to a current manual process, through sophisticated robotic motions. ... for HPV; a virus that has an established link to ...
... Next step toward deploying biometric exit procedures for ... of Homeland Security (DHS) today began collecting biometrics ... citizens departing the United States as part of ... and Detroit Metropolitan Wayne County Airport. Since 2004, ...
Cached Biology Technology:Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 7Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 8Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 9Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 10Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 11Plexus Awarded Development Contract With QIAGEN 2Plexus Awarded Development Contract With QIAGEN 3Plexus Awarded Development Contract With QIAGEN 4DHS Begins Test of Biometric Exit Procedures at Two U.S. Airports 2
(Date:8/29/2014)... Ebola researcher from the University of Texas Medical Branch at ... three monoclonal antibodies can completely protect monkeys against a lethal ... at a time when the disease is severe. , Thomas ... for Nature discussing advances in Ebola treatment research. ... among the most deadly of pathogens, with fatality rates of ...
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2CCNY team defines new biodiversity metric 2Assortativity signatures of transcription factor networks contribute to robustness 2
... has provided the first conclusive evidence that neurodevelopmental ... such as Alzheimer's disease, Parkinson's disease and ataxias ... specific gene defects that interfere with the electrical ... neurons. , The implicated gene, KCNC3, and two ...
... evolution of Earth's first animals will have to be ... according to a new study by Indiana University Bloomington ... of the National Academy of Sciences. , Purported ... last 12 years, mainly by paleontologists working in China. ...
... not only make teens more aggressive, but may keep ... ultimately wears off but there may be other, lasting ... in February's Behavioral Neuroscience, also showed that aggression rose ... the brain's aggression control region. Behavioral Neuroscience is ...
Cached Biology News:Study ties 'new' cell-death mechanism to developmental and degenerative brain disorders 2Study ties 'new' cell-death mechanism to developmental and degenerative brain disorders 3Embryos tell story of Earth's earliest animals 2Embryos tell story of Earth's earliest animals 3Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 2Animal models show that anabolic steroids flip the adolescent brain's switch for aggression 3
... which can immunocapture up to 50 g ... included are 2 mg of bovine heart ... immunocapture kit allows isolation of the ATP ... of tissue. This facilitates subsequent analysis of ...
ASCIZ...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Biology Products: